BRAF and cancer: Most cancers with atypical KRAS mutations (291/335, 86.9%) had no additional mutations in BRAF, NRAS, or NF1, with the incidence of these mutations being far lower than the incidence of concomitant Ras mutations in atypical BRAF colorectal cancers (Table 1).